Bioactivity

Bioactivity refers to a peptide's ability to exert a measurable biological effect in a living system or relevant in vitro model. It is the central indicator of a molecule's scientific interest: without demonstrated bioactivity, a peptide is merely a chemical assembly with no research value.

Bioactivity evaluation relies on a battery of complementary approaches. In vitro: receptor binding assays (SPR, fluorescence polarization), cellular functional assays (cAMP, intracellular calcium, kinase phosphorylation, cell proliferation, migration, angiogenesis), enzymatic assays (protease inhibition, catalytic activity modulation). In vivo (RUO animal models): physiological measurements (glycemia, weight, blood pressure, wound healing), biochemical analyses (hormonal profiles, inflammatory markers), tissue histology.

Key parameters include EC₅₀ (concentration producing 50% maximal effect), IC₅₀ (concentration inhibiting 50% of an activity), Emax (maximum achievable effect), relative selectivity between related receptors, therapeutic window (ratio between active dose and toxic dose in a model).

For catalog research peptides, documented bioactivity is an absolute prerequisite of scientific value. A peptide with 99% chemical purity but collapsing bioactivity (wrong sequence, oxidation, incorrect folding, enantiomer) has no experimental interest. Characterization analyses must therefore include, beyond HPLC and mass, functional tests confirming that the delivered molecule indeed reproduces the expected effects from reference literature.

Bioactivity is also highly context-dependent: a peptide may be active on one cell type and inactive on another, active at physiological pH and inactive at acidic pH, active fresh and inactive after prolonged storage. Controlling all these variables is the core of rigorous methodology in RUO peptide research, and distinguishes a publishable result from an unusable artifact.